A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Completed · Phase 3 · Has a placebo group

Conditions studied: Metastatic Breast Cancer

In brief

The primary objective of the study is to assess the progression-free survival (PFS) of veliparib in combination with carboplatin and paclitaxel (C/P) compared to placebo plus C/P in participants with a Breast Cancer Gene 1 or 2 (BRCA1; BRCA2) mutation in Human Epidermal Growth Factor Receptor 2 (HER2)-negative metastatic or locally advanced unresectable breast cancer. The secondary objectives of the study are to assess overall survival (OS), clinical benefit rate (CBR) through the end of Week 24, objective response rate (ORR) and PFS on subsequent therapy (PFS2) in participants treated with veliparib in combination with C/P versus placebo in combination with C/P.

Key facts

Study ID

NCT02163694

Run by

AbbVie

People needed

513

Starts

2014-04-08

Expected to finish

2024-01-25

Last updated by the study team

2025-02-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed breast cancer that is either locally advanced or metastatic. Locally advanced breast cancer must not be amenable to surgical resection or radiation with curative intent.
• Suspected deleterious or deleterious Breast Cancer Gene 1 (BRCA1) and/or Breast Cancer Gene 2 (BRCA2) germline mutation.
• Breast cancer must be Human Epidermal Growth Factor Receptor 2 (HER2)-negative.
• Measurable or non-measurable (but radiologically evaluable) disease per Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1 on computed tomography (CT) scan (within 28 days of randomization) with at least one lesion outside previously irradiated areas.
• Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2.
• Adequate hematologic, renal, and hepatic function (within 28 days of randomization).

You may not qualify if…

• More than two prior lines of cytotoxic chemotherapy (e.g., gemcitabine, doxorubicin, capecitabine) for metastatic disease.
• Regimens received in the adjuvant/neoadjuvant setting or for locally advanced breast cancer within the past 6 months will also be considered toward the maximum of 2 prior lines of therapy. Adjuvant/neoadjuvant chemotherapy for one cancer event will count as one prior line of therapy, if received within the past 6 months.
• Previous treatments with hormonal therapy (tamoxifen, aromatase inhibitors) and signal transduction agents (e.g., erlotinib, gefitinib, everolimus, bevacizumab) are allowed and are not counted towards the prior line of therapy.
• Progressed or recurred within 12 months of completing platinum therapy or received > 1 prior line of platinum therapy for breast cancer in any setting (adjuvant, neoadjuvant, or metastatic).
• Prior therapy with Poly(ADP-ribose)-Polymerase (PARP) inhibitors.
• Prior taxane therapy administered for the treatment of metastatic breast cancer with the below exceptions.
• Prior taxane therapy for metastatic breast cancer is allowed if the patient received ≤ 1 full cycle (i.e., therapy discontinued within 4 weeks for subjects receiving weekly paclitaxel or Abraxane; therapy discontinued within 3 weeks for subjects receiving paclitaxel or docetaxel every 3 weeks) in the absence of progression or if taxane therapy for metastatic disease was > 12 months prior to Cycle 1 Day-2 (C1D-2).
• Use of taxanes as adjuvant therapy or to treat locally advanced disease is permitted, if given more than 6 months prior to C1D-2
• Known history of allergic reaction to cremophor-paclitaxel, carboplatin, Azo-Colourant Tartrazine (also known as FD\&C Yellow 5 or E102), Azo-Colourant Orange Yellow-S (also known as FD\&C Yellow 6 or E110) or known contraindications to any study supplied drug.
• Active CNS metastases or leptomeningeal disease.

Where it is running

• Hematology and Oncology Assoc /ID# 130058 — Newport Beach, California, United States
• Cancer Research Collaboration /ID# 128860 — Santa Ana, California, United States
• Icri /Id# 128520 — Whittier, California, United States
• Univ of Colorado Cancer Center /ID# 124983 — Aurora, Colorado, United States
• Saint Joseph Hospital /ID# 131768 — Denver, Colorado, United States
• Norwalk Hospital /ID# 133509 — Norwalk, Connecticut, United States
• Lynn Cancer Institute, Boca /ID# 125013 — Boca Raton, Florida, United States
• Holy Cross Hospital /ID# 125012 — Fort Lauderdale, Florida, United States
• Sacred Heart Hospital /ID# 128279 — Pensacola, Florida, United States
• Moffitt Cancer Center /ID# 124990 — Tampa, Florida, United States
• Florida Cancer Specialists - East /ID# 125007 — West Palm Beach, Florida, United States
• Emory Midtown Infectious Disease Clinic /ID# 133192 — Atlanta, Georgia, United States
• The Cancer Ctr at DeKalb Med C /ID# 125024 — Decatur, Georgia, United States
• University of Illinois - Chicago /ID# 127576 — Chicago, Illinois, United States
• NorthShore University HealthSystem /ID# 124996 — Evanston, Illinois, United States
• Midwestern Regional CTC /ID# 124986 — Zion, Illinois, United States
• McFarland Clinic, PC /ID# 129904 — Ames, Iowa, United States
• Johns Hopkins University /ID# 125015 — Baltimore, Maryland, United States
• Baystate Medical Center /ID# 139461 — Springfield, Massachusetts, United States
• UMass Chan Medical School /ID# 129067 — Worcester, Massachusetts, United States
• Henry Ford Health System /ID# 134497 — Detroit, Michigan, United States
• Spectrum Health Medical Group /ID# 133568 — Grand Rapids, Michigan, United States
• Spectrum Health Medical Group /ID# 148471 — Grand Rapids, Michigan, United States
• William Beaumont Hospital /ID# 125019 — Royal Oak, Michigan, United States
• Moores Cancer Center at UC San Diego /ID# 124991 — La Jolla, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.